| December 29, 2004 |
Telik Completes Enrollment in ASSIST-1, Initiates ASSIST-3 and Reviews Status of ASSIST-2 Clinical Trials |
| December 17, 2004 |
Telik Comments on ASSIST-2 Trial |
| December 5, 2004 |
Telik Announces Positive Data from Phase 2 Trial of Telintra in Myelodysplastic Syndrome |
| November 29, 2004 |
Telik Announces Presentation at Lazard First Annual Life Sciences Conference |
| November 15, 2004 |
Telik Announces Webcast of Presentation at CSFB Healthcare Conference |
| November 04, 2004 |
Telik Announces Third Quarter 2004 Financial Results |
| October 04, 2004 |
Telik Announces Positive Results From Phase 2 Trial of Telcyta in Combination with Doxil |
| October 04, 2004 |
Telik Announces Positive Results From Phase 2 Trial of Telcyta in Combination with Carboplatin |
| September 23, 2004 |
Telik Announces Webcast of Presentation at UBS Global Life Sciences Conference |
| September 21, 2004 |
Telik Announces Publication on Novel Application of Trap Drug Discovery Technology |
|
September
7, 2004 |
Telik Announces Presentation at Newsmakers
in the Biotech Industry Conference |
| September
3, 2004 |
Telik
Announces Webcast of Presentation at Thomas Weisel Healthcare
Tailwinds 2004 Conference |
| August
27 , 2004 |
Telik
Announces Election of Herwig Von Morzé to Telik Board
of Directors |
| August
5 , 2004 |
Telik
Announces Second Quarter 2004 Financial Results |
| July
29, 2004 |
Telik Announces Quarterly Financial Release, Conference Call and Webcast |
| June
30, 2004 |
Telik Initiates First Triplet Combination Trial with TELCYTA™in Front-Line Treatment of Non-Small Cell Lung Cancer |
| June 15, 2004 |
Telik Announces Webcast of Management Presentation at Needham & Company Biotechnology Conference |
| June
9, 2004 |
Telik Announces Presentation at Pacific Growth Equities Life Sciences Conference |
| June 5, 2004 |
Telik Announces 46% Objective Response Rate in Phase 2 Trial of TELCYTA™ in Combination with Liposomal Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer |
| June 5, 2004 |
Telik Announces 27% Objective Response Rate in Phase 2 Trial of TELCYTA™ in Combination with Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer |
| June 5, 2004 |
Telik Announces 56%
Objective Response Rate of TELCYTA™ in Combination with Carboplatin in Phase 2 Study in Platinum Refractory or Resistant Ovarian Cancer |
| June 3, 2004 |
Telik Announces Presentation at Goldman Sachs 25th Annual Global Healthcare Conference |
| April
29, 2004 |
Telik
Announces First Quarter 2004 Financial Results |
| April
24, 2004 |
Telik
Announces Quarterly Financial Release, Conference Call and Webcast |
| March
30, 2004 |
Telik
Reports Positive TELCYTA™ Data Supporting Use in Combination
Chemotherapy Regimens |
| |
Top |
| March
30, 2004 |
Telik
Announces ASSIST-2: Phase 3 Registration Trial of TELCYTA™
in Advanced Non-Small Cell Lung Cancer |
|
March 25, 2004 |
Telik
Announces TELCYTA™ Presentations at American Association
for Cancer Research Annual Meeting |
| March
9, 2004 |
Telik
Initiates TELCYTA™ Trial in Front-Line Treatment of Non-Small
Cell Lung Cancer |
| March
2, 2004 |
Telik
Announces Successful TRAP Drug Discovery Collaboration with
ROCHE |
|
February 26, 2004 |
Telik Announces Webcast of Presentation at Lehman Brothers Global
Healthcare Conference |
|
February 23, 2004 |
Telik Announces Presentations at BIO CEO AND Investor Conference |
|
February 19, 2004 |
Telik Announces Fourth Quarter and Year End 2003 Financial Results. |
|
February 17, 2004 |
Telik
Announces Quarterly Financial Release, Conference Call and Webcast |
|
February 3, 2004 |
Telik Announces Webcast of Presentation at Merrill Lynch Global
Pharmaceutical, Biotechnology and Medical Device Conference |
|
January 23, 2004 |
Telik Announces Webcast of Presentation at Piper Jaffray Health
Care Conference |
| |
Top |
